Evoke Pharma (EVOK) Competitors $4.33 -0.17 (-3.78%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EVOK vs. LGVN, HCWB, MRKR, DRRX, NAII, PLUR, BLRX, ATHA, EQ, and GOVXShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Longeveron (LGVN), HCW Biologics (HCWB), Marker Therapeutics (MRKR), DURECT (DRRX), Natural Alternatives International (NAII), Pluri (PLUR), BioLineRx (BLRX), Athira Pharma (ATHA), Equillium (EQ), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Longeveron HCW Biologics Marker Therapeutics DURECT Natural Alternatives International Pluri BioLineRx Athira Pharma Equillium GeoVax Labs Longeveron (NASDAQ:LGVN) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do insiders & institutionals have more ownership in LGVN or EVOK? 10.0% of Longeveron shares are owned by institutional investors. 19.1% of Longeveron shares are owned by insiders. Comparatively, 6.1% of Evoke Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor LGVN or EVOK? In the previous week, Evoke Pharma had 1 more articles in the media than Longeveron. MarketBeat recorded 1 mentions for Evoke Pharma and 0 mentions for Longeveron. Longeveron's average media sentiment score of 0.00 equaled Evoke Pharma'saverage media sentiment score. Company Overall Sentiment Longeveron Neutral Evoke Pharma Neutral Does the MarketBeat Community believe in LGVN or EVOK? Evoke Pharma received 347 more outperform votes than Longeveron when rated by MarketBeat users. However, 92.86% of users gave Longeveron an outperform vote while only 59.90% of users gave Evoke Pharma an outperform vote. CompanyUnderperformOutperformLongeveronOutperform Votes1392.86% Underperform Votes17.14%Evoke PharmaOutperform Votes36059.90% Underperform Votes24140.10% Which has stronger valuation & earnings, LGVN or EVOK? Evoke Pharma has higher revenue and earnings than Longeveron. Evoke Pharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$710K39.50-$21.41M-$6.28-0.30Evoke Pharma$5.18M1.25-$7.79M-$10.99-0.39 Do analysts prefer LGVN or EVOK? Longeveron currently has a consensus target price of $8.00, suggesting a potential upside of 323.28%. Given Longeveron's stronger consensus rating and higher possible upside, equities analysts clearly believe Longeveron is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Evoke Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is LGVN or EVOK more profitable? Evoke Pharma has a net margin of -71.32% compared to Longeveron's net margin of -967.49%. Longeveron's return on equity of -142.43% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-967.49% -142.43% -100.84% Evoke Pharma -71.32%-308.49%-53.66% Which has more risk & volatility, LGVN or EVOK? Longeveron has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. SummaryLongeveron beats Evoke Pharma on 10 of the 16 factors compared between the two stocks. Ad DTIEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.45M$6.59B$5.21B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-0.396.7882.8815.55Price / Sales1.25357.041,246.7687.28Price / CashN/A53.8240.9136.92Price / Book1.4710.617.206.55Net Income-$7.79M$153.27M$119.63M$226.22M7 Day Performance-5.46%3.97%2.12%3.77%1 Month Performance-15.59%-6.72%-2.43%4.64%1 Year Performance-71.24%33.26%34.53%29.21% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.0538 of 5 stars$4.33-3.8%N/A-71.2%$6.45M$5.18M-0.394Analyst ForecastLGVNLongeveron1.7757 of 5 stars$1.87+1.1%$8.00+327.8%-90.1%$26.85M$710,000.00-0.3023HCWBHCW Biologics1.0689 of 5 stars$0.71-25.3%N/A-30.3%$26.84M$2.84M-0.7140News CoverageMRKRMarker Therapeutics3.5534 of 5 stars$2.99-6.0%$19.00+535.5%+15.7%$26.67M$3.31M0.0060Gap DownDRRXDURECT3.1145 of 5 stars$0.85-5.6%$5.00+487.8%+55.4%$26.41M$8.55M-1.3980Analyst ForecastGap UpNAIINatural Alternatives International0.3565 of 5 stars$4.25-3.8%N/A-31.5%$26.35M$113.80M-2.88290News CoveragePLURPluri0.0812 of 5 stars$4.70-7.1%N/A-1.2%$26.13M$330,000.00-0.78150BLRXBioLineRx1.9966 of 5 stars$0.32-40.5%$21.00+6,396.5%-81.7%$25.84M$4.80M-0.7240News CoverageHigh Trading VolumeATHAAthira Pharma2.8227 of 5 stars$0.67+3.1%$13.83+1,977.7%-57.3%$25.75MN/A-0.2340Gap DownEQEquillium3.4616 of 5 stars$0.73+1.4%$5.00+589.7%+42.2%$25.69M$36.08M-5.1840Gap DownGOVXGeoVax Labs2.8091 of 5 stars$2.70+3.4%$13.25+390.7%-61.5%$25.49M$80,000.000.0017Analyst Revision Related Companies and Tools Related Companies LGVN Alternatives HCWB Alternatives MRKR Alternatives DRRX Alternatives NAII Alternatives PLUR Alternatives BLRX Alternatives ATHA Alternatives EQ Alternatives GOVX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVOK) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
